Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Pyruvic acid

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Pyruvic acid: Sponsors, patents, clinical trial progress

Pyruvic acid is an investigational drug.

There have been 7 clinical trials for Pyruvic acid. The most recent clinical trial was a Phase 1 trial, which was initiated on March 1st 2011.

The most common disease conditions in clinical trials are Hepatitis, Chronic, Renal Insufficiency, and Hepatitis B, Chronic. The leading clinical trial sponsors are Isfahan University of Medical Sciences, UPECLIN HC FM Botucatu Unesp, and Beijing 302 Hospital.

There are two hundred and sixty-eight US patents protecting this investigational drug and two international patents.

Recent Clinical Trials for Pyruvic acid
Modified Jessner's Solution With Trichloroacetic Acid Versus Glycolic Acid With Trichloroacetic AcidAssiut UniversityPhase 4
Metabolic Imaging of the Heart Using Hyperpolarized (13C) Pyruvate InjectionSunnybrook Health Sciences CentrePhase 1
Pyruvic Acid Versus Salicylic Acid Preparation in Treatment of Plantar WartsIsfahan University of Medical SciencesPhase 2/Phase 3

See all Pyruvic acid clinical trials

Clinical Trial Summary for Pyruvic acid

Top disease conditions for Pyruvic acid
Top clinical trial sponsors for Pyruvic acid

See all Pyruvic acid clinical trials

US Patents for Pyruvic acid

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Pyruvic acid   Start Trial Carbaphens: aprophen analogs that are binary antidotes for organophosphate poisoning The United States of America, as represented by the Secretary of the Army (Washington, DC)   Start Trial
Pyruvic acid   Start Trial Enzymatic process for preparing N-acetylneuraminic acid Forschungszentrum Juelich GmbH (Juelich, DE) Ciba-Geigy Corporation (Ardsley, NY)   Start Trial
Pyruvic acid   Start Trial Insecticidal pyrazolines E. I. Du Pont de Nemours and Company (Wilmington, DE)   Start Trial
Pyruvic acid   Start Trial Organic photochromic compound, a dimer of pyrido quinoline Seikisui Kagaku Kogyo Kabushiki Kaisha (JP)   Start Trial
Pyruvic acid   Start Trial Decahydroisoquinoline carboxylic acids Hoechst Aktiengesellschaft (Frankfurt am Main, DE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Pyruvic acid

Drugname Country Document Number Estimated Expiration Related US Patent
Pyruvic acid Austria 129016 2009-11-15   Start Trial
Pyruvic acid Australia 639035 2009-11-15   Start Trial
Pyruvic acid Australia 6587290 2009-11-15   Start Trial
Pyruvic acid Canada 2029984 2009-11-15   Start Trial
Pyruvic acid Germany 3937891 2009-11-15   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Express Scripts
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.